AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01755156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to glimepiride
Description: Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
Study NCT01755156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
Study NCT01755156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
Study NCT01755156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continue stable pre-study dose of metformin tablet(s) administered orally (>= 1500 mg daily) throughout the study.
Study NCT01755156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants continue stable pre-study dose of metformin tablet(s) administered orally (>= 1500 mg daily) throughout the study.
Study NCT03142451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX103 minocycline foam 1.5%
Description: Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study NCT03142451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study NCT01404260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
Study NCT01404260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine +Carboplatin
Description: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
Study NCT01404260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine +Carboplatin
Description: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
Study NCT00901563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigaptide
Description: Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
Study NCT00901563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
Study NCT00901563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
Study NCT02074137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL XRP6258
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study NCT02074137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT02074137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT02376335 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
Study NCT02376335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
Study NCT02832947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban 10 mg
Description: At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
Study NCT01749566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc
Description: Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
Study NCT01186497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
Study NCT01186497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
Study NCT04404439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline + topiramate
Description: Treatment group 1
Study NCT04404439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil + paroxetine
Description: Treatment group 2
Study NCT04404439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT03307096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microperc surgery
Description: Parents are treated by Microperc Percutaneous Nephrolithotomy
Study NCT03307096 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FURS
Description: Parents are treated by FURS
Study NCT03225222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: prostate biopsy
Study NCT01795131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Study NCT04170634 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation
Description: Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
Study NCT02785289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal swab
Description: Vaginal cell collection will be performed with the two types of indicated swab.
Study NCT03800303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based treatment
Description: 2-week family-based treatment
Study NCT00437970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15mg of Pioglitazone taken orally twice a day
Study NCT00437970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg of Metformin taken orally twice a day
Study NCT01795131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01990352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
Study NCT00949078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
Study NCT02916238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
Study NCT02916238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
Study NCT03682393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
Study NCT03682393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
Study NCT00477217 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zoledronic acid
Study NCT03737032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
Study NCT01676597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline and rifaximin
Description: Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
Study NCT01676597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and placebo
Description: Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
Study NCT00735189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anticoagulation clinic care
Description: Patient receives care from the outpatient anticoagulation management service
Study NCT00735189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: patient receives usual anticoagulation care from their regular primary care physician
Study NCT02263170 — intervention group
Intervention type: OTHER
Intervention: MRI (magnetic resonance imaging)
Description: Assessment of the sphincter morphology
Study NCT02263170 — intervention group
Intervention type: OTHER
Intervention: US (ultra sound)
Description: Assessment of the sphincter morphology
Study NCT02263170 — intervention group
Intervention type: OTHER
Intervention: FLIP (functional luminal imaging probe)
Description: Assessment of the biomechanical properties of the sphincter region
Study NCT02263170 — intervention group
Intervention type: OTHER
Intervention: HRAM (high resolution anal manometry)
Description: Assessment of the biomechanical properties of the sphincter region
Study NCT00059761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01753778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Touch III Device
Description: Treatment with Cryo-Touch III
Study NCT01488474 — intervention group
Intervention type: PROCEDURE
Intervention: peripheral nerve stimulation
Description: defining the minimal current threshold for distal motor response
Study NCT04158648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
Study NCT00345787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo is applied for 12weeks
Study NCT00345787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System
Description: Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
Study NCT03069339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
Study NCT03069339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Variceal Ligation
Description: EVL will be done every 3 weeks till eradication
Study NCT03069339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Ligation
Description: EVL will be done every 3 weeks till eradication
Study NCT04076761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
Study NCT00917410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS support
Description: The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~1. Remember to take your preventive asthma medication (sent at 8.00 am).~2. Were you awakened during the night due to your asthma? Answer YES or NO.~3. How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~4. What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study).
Study NCT03572634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0903
Description: Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression.
Study NCT03572634 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TP-0903 and ibrutinib combination therapy
Description: Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period).
Study NCT02100553 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CE/BZA
Description: CE 0.45mg/BZA 20mg tablets, single dose
Study NCT02100553 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Two 100 mg capsules, once daily for 7 days
Study NCT02100553 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CE/BZA
Description: CE 0.45mg/BZA 20mg tablets, single dose on Day 5
Study NCT02396862 — intervention group
Intervention type: DRUG
Intervention: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Description: Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
Study NCT02525224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutritional Supplement
Description: 2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
Study NCT01312155 — intervention group
Intervention type: OTHER
Intervention: Intubation
Description: Intubation, endotracheal
Study NCT03348683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
Study NCT03348683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
Study NCT03633214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online training module
Description: Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
Study NCT01147939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacytarabine
Description: Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
Study NCT01147939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice
Description: E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
Study NCT01975116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azurin-derived cell-penetrating peptide p28
Description: Given IV
Study NCT03737032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
Study NCT02155803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR Gel (adrenocorticotropic hormone)
Description: ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
Study NCT00598130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fleece
Description: Fibrin Patch
Study NCT00598130 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fleece
Description: Fibrin Patch
Study NCT04086940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: preventive
Study NCT02124850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod
Study NCT03682809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
Study NCT03066973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHING EXERCISE
Description: The intervention group was instructed on breathing exercise according to the established trial protocol.
Study NCT04515862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education
Description: The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
Study NCT02361580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: Subject keeps diary of recovery
Study NCT00531180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4D CT scans
Description: Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.